S9 Ep7: Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis
Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.